A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized clinical study to evaluate the pharmacokinetic (PK)
profiles, safety, tolerability and preliminary efficacy of oral abexinostat monotherapy in
patients with non-Hodgkin's lymphoma who have failed standard of care, and thereby to
determine the pharmacokinetic (PK) parameters, the maximum tolerated dose (MTD), and the
recommended phase 2 dose (RP2D) of the oral monotherapy of abexinostat.